



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Steve Bell, et al.) Group Art Unit: 1645
)
Serial No.: 09/932,538) Examiner: Zeman, Robert A.
)
Filed: August 17, 2001)
)
For: CALCIUM PHOSPHATE PARTICLES)
AS MUCOSAL ADJUVANTS)

Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

Attorney Docket No. 37070/205236

Date: 2/4/04

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the enclosed Form PTO/SB/08 are submitted for consideration by the Examiner. Copies of the cited documents are enclosed.

Submission of the reference provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made, or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.


This Information Disclosure Statement is being filed pursuant to 37 C.F.R. 1.97(b)(3), before issuance of an Office action on the merits and, therefore, Applicants believe that no fee for consideration of this paper is required. The Commissioner is authorized to charge any fees that may be due or credit any overpayment to Deposit Account No. 11-0855.

U.S. Serial No. 09/932,538

Filed: August 17, 2001

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Respectfully submitted,


Catherine E. Fienning
Reg. No. 54,095

ATTORNEY FOR ASSIGNEE

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-532.6938



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/932,538
April 16, 2003	August 17, 2001
First Named Inventor	Bell, et al.
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	37070/205236

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		He, et al., "Calcium Phosphate Nanoparticle Adjuvant," <i>Clinical and Diagnostic Laboratory Immunology</i> , pp. 899-903 (November 2000)	
		He, et al., "Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection Against Herpes Simplex Virus Type 2," <i>Clinical and Diagnostic Laboratory Immunology</i> , pp. 1021-1024 (September 2002)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.